Online Resource Table 1

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

Philip G. Conaghan[1] · Eduardo Mysler[2] · Yoshiya Tanaka[3] · Barbara Da Silva-Tillmann[4] · Tim Shaw[5] · John Liu[4] · Ryan Ferguson[4] · Jeffrey V. Enejosa[4] · Stanley Cohen[6] · Peter Nash[7] · William Rigby[8] · Gerd Burmester[9]

[1] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, UK (ORCID: 0000-0002-3478-5665)

[2] Organización Médica de Investigación, Buenos Aires, Argentina

[3] The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan (ORCID: 0000-0002-0807-7139)

[4] AbbVie Inc., North Chicago, IL, USA

[5] AbbVie Ltd, Maidenhead, UK

[6] Metroplex Clinical Research Center, Dallas, TX, USA (ORCID: 0000-00002-9226-979x)

[7] Griffith University, Brisbane, Queensland, Australia

[8] Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA (ORCID: 0000-0002-1382-7299)

[9] Charité-Universitätsmedizin Berlin, Berlin, Germany (ORCID: 0000-0001-7518-1131)

Corresponding author: Philip Conaghan (p.conaghan@leeds.ac.uk)

Online Resource Table 1 Overview of the upadacitinib phase III clinical program in RA.

	SELECT-EARLY	SELECT-NEXT	SELECT-COMPARE	SELECT-MONOTHERAPY	SELECT-BEYOND
Patient populations	MTX-naïve	csDMARD-IR	MTX-IR	MTX-IR	Biologic-IR
Scheme	Mono	Combo	Combo	Mono	Combo
Background	—	csDMARDs	MTX	— (PBO group continued MTX)	csDMARDs
Active comparator	MTX	—	ADA	MTX	—
Aims	UPA 7.5 mg (Japan only) (*n* = 55)	—	—	—	—
	UPA 15 mg (*n* = 317)	UPA 15 mg (*n* = 221)	UPA 15 mg (*n* = 651)	UPA 15 mg (*n* = 217)	UPA 15 mg (*n* = 165)
	UPA 30 mg (*n* = 314)	UPA 30 mg (*n* = 219)	ADA 40 mg (*n* = 327)	UPA 30 mg (*n* = 215)	UPA 30 mg (*n* = 165)
	MTX (*n* = 314)	PBO (*n* = 221)	PBO (*n* = 651)	MTX (*n* = 216)	PBO (*n* = 169)
Controlled duration	48 weeks	12 weeks	48 weeks[a]	14 weeks	24 weeks
Total sample size	1002	661	1629	648	499

NCT #	NCT02706873	NCT02675426	NCT02629159	NCT02706951	NCT02706847
Study #	M13-545	M13-549	M14-465	M15-555	M13-542
References	[1, 2]	[3]	[4,5]	[6]	[7]

[a]PBO-controlled period 26 weeks, ADA-controlled period up to ≥ 48 weeks. *ADA* adalimumab, *combo* combination, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *EOW* every other week, *IR* inadequate responder, *mono* monotherapy, *MTX* methotrexate, *PBO* placebo, *RA* rheumatoid arthritis, *UPA* upadacitinib

References

1. van Vollenhoven R, Takeuchi T, Pangan A, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): A randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheum. 2020;[Epub ahead of print].
2. A study to compare upadacitinib (ABT-494) monotherapy to methotrexate (MTX) monotherapy in adults with rheumatoid arthritis (RA) who have not previously taken methotrexate (SELECT-EARLY). https://clinicaltrials.gov/ct2/show/NCT02706873 [Accessed 1 Dec 2020].
3. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial 48. Lancet. 2018;391:2503–12.
4. Fleischmann R, Pangan A, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheum. 2019;71:1788–800.
5. Fleischmann R, Genovese M, Enejosa J, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454–62.
6. Smolen J, Pangan A, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–11.
7. Genovese M, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–24.